Shenzhen Kangtai Biological Products Co., Ltd. (SHE:300601)
China · Delayed Price · Currency is CNY 15.34
+0.09 (0.59%)
Feb 3, 2026, 1:25 PM CST
SHE:300601 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 2,688 | 2,643 | 3,467 | 3,129 | 3,650 | 2,259 |
Other Revenue | 8.88 | 8.88 | 10.9 | 28.11 | 2.33 | 2.32 |
| 2,697 | 2,652 | 3,477 | 3,157 | 3,652 | 2,261 | |
Revenue Growth (YoY) | -11.03% | -23.75% | 10.14% | -13.54% | 61.51% | 16.36% |
Cost of Revenue | 906.94 | 700.7 | 655.29 | 775.09 | 1,148 | 247.14 |
Gross Profit | 1,790 | 1,951 | 2,822 | 2,382 | 2,504 | 2,014 |
Selling, General & Admin | 1,255 | 1,253 | 1,505 | 1,315 | 819.8 | 1,030 |
Research & Development | 616.42 | 508.12 | 500.75 | 801.86 | 354.26 | 267.06 |
Other Operating Expenses | 96.42 | 30.55 | 25.62 | 20.49 | 20.16 | 14.46 |
Operating Expenses | 1,995 | 1,821 | 2,044 | 2,177 | 1,204 | 1,332 |
Operating Income | -204.55 | 129.98 | 778.26 | 205.13 | 1,300 | 682.04 |
Interest Expense | -119.91 | -124.12 | -113.71 | -108.97 | -54.51 | -2.34 |
Interest & Investment Income | 88.93 | 98.85 | 117.32 | 133.57 | 144.63 | 37.74 |
Currency Exchange Gain (Loss) | 0.21 | 0.21 | 0 | -1.82 | -0.35 | -0.01 |
Other Non Operating Income (Expenses) | 5.89 | -0.16 | -0.65 | -0.52 | -4.19 | -0.47 |
EBT Excluding Unusual Items | -229.43 | 104.76 | 781.22 | 227.38 | 1,386 | 716.96 |
Gain (Loss) on Sale of Investments | 0.89 | 1.38 | 0.19 | 3.18 | - | 30.14 |
Gain (Loss) on Sale of Assets | -10.94 | -8.42 | -1.35 | 0.13 | 0.03 | -0.29 |
Asset Writedown | -39.77 | -15.62 | -3.32 | -624.09 | -3.41 | -5.46 |
Other Unusual Items | 94.93 | 67.84 | 163.57 | 55.15 | 56.78 | 31.06 |
Pretax Income | -184.32 | 149.94 | 940.32 | -338.25 | 1,439 | 772.41 |
Income Tax Expense | -83.98 | -51.62 | 79.02 | -205.54 | 175.87 | 93.22 |
Earnings From Continuing Operations | -100.34 | 201.55 | 861.3 | -132.71 | 1,263 | 679.19 |
Minority Interest in Earnings | 0.05 | 0.1 | - | - | - | - |
Net Income | -100.29 | 201.65 | 861.3 | -132.71 | 1,263 | 679.19 |
Net Income to Common | -100.29 | 201.65 | 861.3 | -132.71 | 1,263 | 679.19 |
Net Income Growth | - | -76.59% | - | - | 86.01% | 18.22% |
Shares Outstanding (Basic) | 1,193 | 1,120 | 1,119 | 1,106 | 1,093 | 1,055 |
Shares Outstanding (Diluted) | 1,193 | 1,120 | 1,119 | 1,106 | 1,111 | 1,076 |
Shares Change (YoY) | 6.03% | 0.15% | 1.15% | -0.43% | 3.23% | 5.34% |
EPS (Basic) | -0.08 | 0.18 | 0.77 | -0.12 | 1.16 | 0.64 |
EPS (Diluted) | -0.08 | 0.18 | 0.77 | -0.12 | 1.14 | 0.63 |
EPS Growth | - | -76.62% | - | - | 80.18% | 12.23% |
Free Cash Flow | 433.19 | 131.07 | 314.65 | -764.7 | -888.15 | -786.81 |
Free Cash Flow Per Share | 0.36 | 0.12 | 0.28 | -0.69 | -0.80 | -0.73 |
Dividend Per Share | 0.090 | 0.090 | 0.380 | - | 0.719 | 0.188 |
Dividend Growth | -55.00% | -76.32% | - | - | 283.36% | - |
Gross Margin | 66.37% | 73.58% | 81.16% | 75.45% | 68.57% | 89.07% |
Operating Margin | -7.58% | 4.90% | 22.38% | 6.50% | 35.60% | 30.16% |
Profit Margin | -3.72% | 7.61% | 24.77% | -4.20% | 34.59% | 30.04% |
Free Cash Flow Margin | 16.06% | 4.94% | 9.05% | -24.22% | -24.32% | -34.80% |
EBITDA | 188.09 | 440.66 | 979.66 | 406.08 | 1,705 | 774.97 |
EBITDA Margin | 6.97% | 16.62% | 28.17% | 12.86% | 46.69% | 34.27% |
D&A For EBITDA | 392.64 | 310.68 | 201.39 | 200.95 | 404.71 | 92.93 |
EBIT | -204.55 | 129.98 | 778.26 | 205.13 | 1,300 | 682.04 |
EBIT Margin | -7.58% | 4.90% | 22.38% | 6.50% | 35.60% | 30.16% |
Effective Tax Rate | - | - | 8.40% | - | 12.22% | 12.07% |
Revenue as Reported | 2,697 | 2,652 | 3,477 | 3,157 | 3,652 | 2,261 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.